KRAS is a frequent oncogenic driver in solid tumors, including Non-Small Cell Lung Cancer (NSCLC). KRAS is involved in various signaling pathways that could allow for targeting of KRAS by targeting downstream key transcription factors that mediate oncogene signaling. At the same time, co-occurrence of other mutations alters the signaling pathways and the key transcription factors involved in the disease network. The convergence of these dysregulated pathways to activate key kinases and transcription factors defines master regulators, forming the regulatory logic (i.e.
PD-L1 is an immune checkpoint protein that mediates immune evasion. In Non-Small Cell Lung Cancer (NSCLC), its expression is used to predict the outcome of treatment targeting PD-1/L1. However, clinical benefits do not occur uniformly, and new approaches are needed to assist in selecting patients for immunotherapy.
Gemcitabine and carboplatin/cisplatin (“platinum”)-based combinations are used to treat a wide variety of malignancies including gynecologic, breast, lung, and occult primary cancers. In Non-Small Cell Lung Cancer (NSCLC), these combinations led to a substantial improvement in overall survival. Nevertheless, a large proportion of patients do not respond. An optimal cytotoxic strategy for managing NSCLC and the discovery of predictive biomarkers for cytotoxic chemotherapy to guide treatment selection remain unmet needs in the clinic.
Cytotoxic drugs are hampered by limited efficacy. Hence, a personalized treatment approach matching chemotherapy with appropriate patients remains an unmet need. Genomic heterogeneity creates an opportunity to discern key genomic aberrations and pathways that confer resistance and response to standard treatment options. We conducted a study using the Cellworks Computational Omics Biology Model (CBM) to identify novel genomic biomarkers associated with response among Non-Small Cell Lung Cancer (NSCLC) patients receiving platinum-based treatments.
The Cellworks Singula Therapeutic Response Index (TRI) has been developed to assist clinicians and NSCLC patients in choosing between competing therapeutic options. In contrast to approaches that consider single aberrations, which often yield limited benefit, Cellworks utilizes an individual patient’s next generation sequencing results and a mechanistic multi-omics biology model, the Cellworks Omics Biology Model (CBM), to biosimulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells.
Paclitaxel and carboplatin (PC) is used to treat a wide variety of malignancies including gynecologic, breast, lung, and occult primary cancers. In NSCLC, PC led to a substantial improvement in 1-yr survival from 10% (P alone) to approximately 50% seen with the combination.
Cancer management using cytotoxic drugs is hampered by limited efficacy. Hence, a personalized treatment approach matching chemotherapy with appropriate patients remains a persistent and unmet need in the clinic. Genomic heterogeneity among patients creates an opportunity to discern key genomic aberrations and pathways that confer resistance and response to standard treatment options.
Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies.
